- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01732861
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
December 19, 2019 updated by: Celgene
A MULTICENTER, PHASE 1B, OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND ACTIVITY OF CC-292 IN COMBINATION WITH LENALIDOMIDE IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA
This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated Dose (MTD).
These data will be used to establish a Recommended Phase 2 Dose (RP2D) for the combination of CC-292 and lenalidomide in subjects with Chronic Lymphocytic Leukemia (CLL).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This dose finding study uses a 3 + 3 dose escalation and expansion design to establish the recommended Phase 2 dose.
The starting dose is CC-292 375 mg twice daily and Lenalidomide 10 mg once daily.
After review of the data for dose limiting toxicities (DLTs), the second dose level will be enrolled.
Doses for this second cohort are CC-292 500 mg twice daily and lenalidomide 10 mg once daily.
Additional doses of lenalidomide in combination with CC-292 may be evaluated to accurately determine the maximum tolerated dose.
Once the maximum tolerated dose and/or optimal biologic effect has been ascertained, an expansion cohort of 24 subjects may be enrolled.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Innsbruck, Austria
- Universitätsklinik für Innere Medizin
-
Linz, Austria, 4021
- AKH Linz
-
Salzburg, Austria, 5020
- Universitatsklinik der PMU
-
Wien, Austria, 1090
- Allgemeines Krankenhaus Wien
-
Wien, Austria, 1100
- Medizinische Abteilung-Zentrum fur Onkologie und Hamatologie
-
-
-
-
Alabama
-
Huntsville, Alabama, United States, 35805
- Clearview Cancer Institute Oncology Specialties, P.C
-
-
Indiana
-
Lafayette, Indiana, United States, 47905
- Horizon Oncology Center
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai School of Medicine
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- The West Clinic
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female subjects 18 years of age and older at the time of signing the informed consent document (ICD).
- Body weight at least 50 kg.
- Must have a documented diagnosis of CLL/SLL (International Workshop on Chronic Lymphocytic Leukemia IWCLL Guidelines - Hallek 2008) by investigator assessment.
- Have failed at least 1 previous treatments for CLL/SLL, and have relapsed and/or refractory disease following last prior treatment defined as CLL/SLL that does not achieve at least a partial response (PR) to therapy or that progresses within 6 months of treatment.
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 2 or less.
- Life expectancy of at least 3 months from time of signing ICD.
- Females of childbearing potential (FCBP) must have a negative medically supervised pregnancy test prior to starting study therapy and agree to ongoing pregnancy testing during and after end of study therapy; commit to continued abstinence from heterosexual intercourse or agree to use, comply with two effective methods of contraception without interruption, 28 days prior to starting study drug, during study therapy, and for 28 days after discontinuation of study therapy.
- Male subjects must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy, throughout study drug therapy and dose interruption, and for 28 days after end of study therapy; agree to not donate semen or sperm during study drug therapy and for 28 days after end of study drug therapy.
- All subjects must understand that lenalidomide could have a potential teratogenic risk, agree to abstain from donating blood with taking lenalidomide therapy and following discontinuation of study drug therapy; have an echocardiogram (ECG) or multigated acquisition (MUGA) scan of the heart demonstrating left ventricular ejection fraction (LVEF) at least 50% or the institution's lower limit of normal; have recovered from adverse, toxic effects of prior therapies to equal to or less than 1 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 4.03 except for alopecia and peripheral neuropathy.
Exclusion Criteria:
- Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
- Autologous stem cell transplant within 3 months prior to the time of signature on the ICD Informed Consent Document.
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring parenteral antibiotics; uncontrolled diabetes mellitus; chronic symptomatic congestive heart failure; unstable angina pectoris, angioplasty, stenting, or myocardial infarctions within 6 months prior to the time of signature on the ICD; clinically significant cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia. Subjects with controlled atrial fibrillation that is asymptomatic are eligible.
- Pregnant or lactating females.
- Prior history of malignancies, unless the subject has been free of the disease for 5 years or more prior to the time of signature on the ICD. Exceptions to the 5 years or more time limit include history of basal cell carcinoma of the skin; squamous cell carcinoma of the skin; carcinoma in situ of the cervix; carcinoma in situ of the breast; carcinoma in situ of the bladder; incidental histologic finding of prostate cancer (Tumor/Nodes/Metastasis [TNM] stage of T1a or T1b).
- Known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV).
- Known seropositivity for hepatitis C virus (HCV); hepatitis B virus (HBV).
- Subjects who are at a high risk for a thromboembolic event and are not willing/able to take venous thromboembolic event (VTE) prophylaxis.
Any of the following laboratory abnormalities:
- Absolute Neutrophil Count (ANC) ≤ 1,000 cells/mm3 (1.0 x 109/L)
- Platelet count ≤ 50,000/mm3 (50 x 109/L) unless secondary to bone marrow involvement by recent bone marrow aspiration and bone marrow biopsy
- Serum Aspartate Transaminase/Serum Glutamic-Oxaloacetic Transaminase (AST/SGOT) or Alanine Transaminase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) > 3.0 x upper limit of normal (ULN) or > 5.0 x ULN in cases of documented liver involvement
- Serum bilirubin > 1.5 x ULN or > 3.0 x ULN in cases of Gilbert's Syndrome and documented liver involvement by lymphoma;
- Calculated creatinine clearance using the Cockcroft-Gault formula (Cockcroft,1976)
- Corrected QT interval (QTc) prolongation (defined as a QTc > 450 msec for males and > 470 msec for females [Fridericia's correction]) or other clinically significant ECG abnormalities as assessed by the investigator.
- Chemotherapy, radiotherapy, investigational anticancer therapy or major surgery within 28 days of Day 1 dosing.
- Use of systemic corticosteroids in doses greater than prednisone equivalent to 20 mg/day within 3 weeks prior to study drug dosing.
- Concomitant use of medicines known to cause QT prolongation or torsades de pointes.
- Chronic use of H2 antagonists or proton pump inhibitors or their use within 7 days of first dose.
- Gastrointestinal abnormalities including the inability to take oral medication, requiring intravenous alimentation, or prior surgical procedure affecting absorption.
- Prior treatment with Btk (Bruton's tyrosine kinase) inhibitors.
- Any live vaccinations within 3 weeks from first dose.
- History of hypersensitivity to immunomodulatory drugs (IMiDs) (eg, lenalidomide, thalidomide, pomalidomide).
- Disease transformation (ie, Richter's Syndrome [lymphomas] or prolymphocytic leukemia).
- Patients with uncontrolled hyper or hypothyroidism.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CC-292 + Lenalidomide
|
CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.
Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: Up to 5 years
|
Number of participants with adverse events
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK-Cmax
Time Frame: Up to 15 days
|
Maximum observed plasma concentration
|
Up to 15 days
|
PK-AUC0-∞
Time Frame: Up to 15 days
|
Area under the plasma concentration time curve from time zero extrapolated to infinity.
|
Up to 15 days
|
Percentage of Participants Who Have Received Some Form of Response
Time Frame: Up to 2 years
|
Response rate is defined as the percentage of participants who have achieved some form of response including: a Complete Response (CR), a CR with incomplete bone marrow recovery, a Nodular Partial Response (PR), a Nodal PR or a PR with lymphoctyosis) based on the International Workshop for Chronic Lymphocytic Leukemia and lymphoma guidelines (IWCLL).
|
Up to 2 years
|
PK-Tmax
Time Frame: Up to 15 days
|
Time to maximum observed plasma concentration
|
Up to 15 days
|
PK-λz
Time Frame: Up to 15 days
|
Terminal phase rate constant, determined by linear regression of the terminal points of the log-linear plasma concentration-time curve.
Visual assessment will be used to identify the terminal linear phase of the concentration
|
Up to 15 days
|
PK-t1/2
Time Frame: Up to 15 days
|
Estimate of the terminal elimination half-life in plasma
|
Up to 15 days
|
PK-AUC (0-t)
Time Frame: Up to 15 days
|
Area under the plasma concentration-time curve from time zero to time t, where t is the last measurable time point
|
Up to 15 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: David Liu, MD, Celgene
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 28, 2012
Primary Completion (Actual)
January 23, 2019
Study Completion (Actual)
January 23, 2019
Study Registration Dates
First Submitted
November 14, 2012
First Submitted That Met QC Criteria
November 19, 2012
First Posted (Estimate)
November 26, 2012
Study Record Updates
Last Update Posted (Actual)
December 20, 2019
Last Update Submitted That Met QC Criteria
December 19, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia, B-Cell
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
Other Study ID Numbers
- CC-292-CLL-001
- 2012-003766-41 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia Lymphocytic Chronic B-Cell
-
National Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...United States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic LeukemiaUnited States
-
Fred Hutchinson Cancer Research Center/University...WithdrawnB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia
-
Shanghai Zhangjiang Biotechnology Limited CompanySuspendedB-cell Chronic Lymphocytic LeukemiaChina
-
Mundipharma Research LimitedTerminatedB-cell Chronic Lymphocytic LeukemiaSpain
-
French Innovative Leukemia OrganisationTerminatedB-cell Chronic Lymphocytic Leukemia (B-CLL)France
-
Genzyme, a Sanofi CompanyBayer Healthcare Pharmaceuticals, Inc./Bayer Schering PharmaCompletedB-Cell Chronic Lymphocytic Leukemia (B-CLL)United Kingdom, Belgium, France, United States, Czech Republic, Serbia
-
National Cancer Institute (NCI)TerminatedB-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic LeukemiaUnited States
-
Genzyme, a Sanofi CompanyCompletedB Cell Chronic Lymphocytic LeukemiaUnited States
-
CelgeneCompletedB-cell Chronic Lymphocytic LeukemiaUnited States, Spain, United Kingdom, Canada, Belgium, Czechia, Hungary, Italy, Poland, Israel, Germany, Ireland, France, New Zealand, Denmark, Australia, Netherlands, Romania, Russian Federation, Sweden, Austria, South Africa, Colo... and more
Clinical Trials on CC-292
-
CelgeneCompleted
-
CelgeneTerminatedLymphoma, Large B-Cell, DiffuseUnited States, France, Canada, Italy
-
Celgene CorporationCompletedLeukemia Lymphocytic Chronic B-CellUnited States, Germany
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell CarcinomaUnited States
-
Loxo Oncology, Inc.Eli Lilly and CompanyActive, not recruiting
-
Eli Lilly and CompanyLoxo Oncology, Inc.CompletedHealthy | Hepatic ImpairmentUnited States
-
Loxo Oncology, Inc.Eli Lilly and CompanyCompletedHealthyUnited States
-
Eli Lilly and CompanyLoxo Oncology, Inc.Completed
-
The Lymphoma Academic Research OrganisationCelgene CorporationCompletedRelapsed/Refractory B-cell LymphomaFrance
-
Loxo Oncology, Inc.Eli Lilly and CompanyAvailableBreast Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Colon Cancer | Medullary Thyroid Cancer | Papillary Thyroid Cancer | Other Solid Tumors With Evidence of Activating RET AlterationSpain, United States, Australia, France, Germany, Israel, Italy, Japan, New Zealand, Poland, Singapore, Switzerland